Introduction: Peptide vs Metabolic Neuroprotection
Neuroprotection research encompasses diverse molecular strategies for preserving neuronal structure and function. Two of the most discussed approaches involve Semax (an ACTH(4-10) analog that upregulates neurotrophic factors) and NAD+ (a coenzyme that supports sirtuin-mediated neuroprotection and mitochondrial function). These represent fundamentally different intervention strategies — neurotrophic factor signaling versus metabolic-epigenetic maintenance — targeting distinct aspects of neuronal vulnerability.
Semax: Neurotrophic Factor Approach
Semax (Met-Glu-His-Phe-Pro-Gly-Pro, MW ~813 Da) stimulates BDNF and NGF production in hippocampus, prefrontal cortex, and basal forebrain. These neurotrophins support synaptic plasticity, LTP, neuronal survival, and cholinergic function. Additional mechanisms include dopaminergic enhancement, serotonin modulation, and neuroinflammation suppression (IL-1beta, TNF-alpha reduction). Approved in Russia for stroke recovery and cognitive enhancement. Decades of clinical safety data. Intranasal delivery provides rapid brain access (15-30 min onset).
NAD+: Metabolic-Epigenetic Approach
NAD+ (MW ~663 Da, administered as precursors NMN or NR) supports neuroprotection through multiple mechanisms: SIRT1 activation (deacetylates p53, NF-kB, PGC-1alpha for neuroprotection and mitochondrial biogenesis), SIRT3 activation (maintains mitochondrial health and oxidative phosphorylation), PARP-1 DNA repair (essential for maintaining genomic integrity in post-mitotic neurons), and CD38 regulation. Brain NAD+ declines ~30-50% with aging, correlating with cognitive decline and neurodegeneration susceptibility.
Evidence: NR supplementation improves cognitive function in Alzheimer mouse models (Hou et al., 2018). NMN restores cerebrovascular function and neurovascular coupling in aged mice (Tarantini et al., 2019). Multiple human clinical trials demonstrate safety of NMN/NR supplementation. NAD+ IV therapy studied for neurological conditions.
Mechanism Comparison
Semax targets neuronal signaling: Enhances neurotrophic support (BDNF/NGF), synaptic plasticity (LTP), and acute neuroprotection (anti-inflammatory, anti-apoptotic). Best for: acute brain injury (stroke), cognitive enhancement, attention/focus, and conditions where neurotrophic factor deficiency is implicated.
NAD+ targets neuronal metabolism: Maintains mitochondrial function, DNA repair capacity, epigenetic regulation (sirtuin-dependent), and cellular energy production. Best for: chronic neurodegeneration, age-related cognitive decline, metabolic aspects of brain aging, and conditions involving mitochondrial dysfunction or NAD+ depletion.
Complementary: Semax enhances neuronal signaling capacity while NAD+ maintains the metabolic infrastructure neurons need to respond to those signals. A neuron with high BDNF stimulation but depleted NAD+ cannot fully activate plasticity pathways. Conversely, a neuron with adequate NAD+ but no neurotrophic stimulation lacks the signals directing plasticity.
Comparison Table
| Feature | Semax | NAD+ (NMN/NR) |
|---|---|---|
| Class | Neuropeptide (ACTH analog) | Coenzyme (nucleotide) |
| MW | ~813 Da | ~663 Da (NMN: ~334 Da) |
| Primary Mechanism | BDNF/NGF upregulation | Sirtuin activation, PARP DNA repair |
| Target | Neuronal signaling and plasticity | Neuronal metabolism and maintenance |
| Acute Neuroprotection | Strong (anti-inflammatory, anti-apoptotic) | Moderate (metabolic support) |
| Chronic Neuroprotection | Moderate (sustained neurotrophic support) | Strong (metabolic maintenance, DNA repair) |
| Cognitive Enhancement | Direct (BDNF-mediated plasticity, attention) | Indirect (metabolic optimization) |
| Route | Intranasal (primary), SC | Oral (NMN/NR), IV (NAD+) |
| Onset | 15-30 minutes (intranasal) | Days to weeks (NAD+ level restoration) |
| Regulatory Status | Approved in Russia (prescription) | NMN/NR: dietary supplements |
| Clinical Trials | Multiple (stroke, cognition, ADHD) | Multiple (NMN/NR metabolic/cognitive) |
| Safety Data | Extensive (decades of clinical use) | Good (NMN/NR well-tolerated) |
Research Applications
Choose Semax: Acute neuroprotection (stroke/TBI models), BDNF/NGF biology, cognitive enhancement studies, attention/focus research, nootropic protocol development, conditions with neurotrophic factor deficiency.
Choose NAD+ (NMN/NR): Chronic neurodegeneration models (Alzheimer, Parkinson), age-related cognitive decline, mitochondrial dysfunction research, sirtuin biology, cerebrovascular aging, metabolic brain health.
Combination: Neurotrophic signaling (Semax) + metabolic maintenance (NAD+) addresses both functional and metabolic aspects of neuroprotection. Theoretically synergistic: NAD+ provides the metabolic substrate needed for BDNF-stimulated plasticity processes. Related peptide MOTS-c also influences mitochondrial function and may complement NAD+ approaches.
Conclusion
Semax and NAD+ represent complementary approaches to neuroprotection targeting different biological levels. Semax provides direct neurotrophic factor enhancement for acute neuroprotection and cognitive enhancement. NAD+ provides metabolic infrastructure maintenance for chronic neuroprotection and cellular energy support. Together, they address the full spectrum of neuronal vulnerability from signaling deficits to metabolic decline.
References
- Dolotov OV, et al. Brain Res. 2006;1117(1):54-60.
- Hou Y, et al. Proc Natl Acad Sci USA. 2018;115(8):E1876-E1885.
- Tarantini S, et al. Redox Biol. 2019;24:101192.
- Gusev EI, et al. Zh Nevrol Psikhiatr. 1997;97(6):26-34.
- Imai S, Guarente L. Trends Cell Biol. 2014;24(8):464-471.
- Glazova NY, et al. Dokl Biol Sci. 2005;404:339-341.
- Verdin E. Science. 2015;350(6265):1208-1213.
- Ashmarin IP, et al. Neurosci Behav Physiol. 1999;29(2):163-167.
For educational and research purposes only. Visit Proxiva Labs for research-grade Semax and other peptides.